Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Hefty Hirudoid Prescriptions Now under Scrutiny, Chuikyo Members at Odds over Restrictions
November 6, 2017
- Heads of Medicines Regulatory Agencies Agree to Promote Global Harmonization to Enable Use of Real World Data as Evidence
November 2, 2017
- Payer Rep Calls on Govt to Promote Use of Formularies at Hospitals to Ensure Use of Cheaper Option: Chuikyo
November 2, 2017
- Clinical Research Review System Based on Clinical Research Law to Start at Minimum of 11 Locations: MHLW
November 2, 2017
- PM Abe Watchful of Reward for Me-Too Drugs, CEFP Minutes Reveal
November 1, 2017
- Chuikyo Moots Possible Expansion of “Essential Drugs”; MHLW Pitches Antibacterial Eye Drops
October 30, 2017
- Kamoya Leaves Chuikyo as Industry Rep, Lauds Breakthrough for Essential Drug Rule
October 30, 2017
- Opdivo Could Face Deeper Cut with Revision of Dosage-Change Re-Pricing Rule; Keytruda Could Be Affected Too
October 30, 2017
- CEFP Kicks Off FY2018 Budget Debate with Major Focus on Scope of Off-Year Price Survey, Revision
October 27, 2017
- MHLW Issues Notification Revising GPSP Ordinance in Response to Medical Information Database
October 27, 2017
- Scrap Price Maintenance Premium, or Limit Scope of Products: MOF
October 26, 2017
- Chuikyo Proposes 5% ICER Deduction for Each Ethical/Societal Criteria Met
October 26, 2017
- Chuikyo OKs “5 Million Yen,” “10 Million Yen” Thresholds for 3-Segment CEA Price Adjustment Model
October 26, 2017
- Payer Rep Insists CEA-Based Price Hike “Not an Option,” MHLW Wants “Grounds” for That Argument: Chuikyo
October 26, 2017
- Consumer Representative on MHLW Advisory Panel Resigns after Taking Regular Payments from Megmilk Snow Brand
October 26, 2017
- Patient Dies due to Mix-Up of Lixiana, Rifxima; PMDA, Companies Issue Warning Statement
October 26, 2017
- Cabinet Approves 5-Year Plan to Promote Anticancer Measures
October 26, 2017
- Sanofi’s Dupilumab, Chugai’s PD-L1 Inhibitor and More Up for MHLW Panel Review on Nov. 6
October 25, 2017
- Conditional Early Approval System Gets Underway: MHLW
October 23, 2017
- LDP Healthcare Big Names Handily Nab Seats in Snap Election
October 23, 2017
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…